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Abstract
Background: Bipolar disorders affect between 3–5% of the population and are associated with
considerable lifelong impairment. Since much of the morbidity associated with bipolar disorder is
caused by recurrent depressive symptoms, which are often only poorly responsive to
antidepressants, there is a need to develop alternative, non-pharmacological interventions.
Psychoeducational interventions have emerged as promising long-term therapeutic options for
bipolar disorder.
Methods/design: The study is an exploratory, individually randomised controlled trial. The
intervention known as 'Beating Bipolar' is a psychoeducational programme which is delivered via a
novel web-based system. We will recruit 100 patients with a diagnosis of DSM-IV bipolar disorder
(including type I and type II) currently in clinical remission. The primary outcome is quality of life.
This will be compared for those patients who have participated in the psychoeducational
programme with those who received treatment as usual. Quality of life will be assessed immediately
following the intervention as well as 10 months after randomisation. Secondary outcomes include
current depressive and manic symptoms, number of episodes of depression and mania/hypomania
experienced during the follow-up period, global functioning, functional impairment and insight. An
assessment of costs and a process evaluation will also be conducted which will explore the
feasibility and acceptability of the intervention as well as potential barriers to effectiveness.
Discussion: Bipolar disorder is common, under-recognised and often poorly managed. It is a
chronic, life-long, relapsing condition which has an enormous impact on the individual and the
economy. This trial will be the first to explore the effectiveness of a novel web-based
psychoeducational intervention for patients with bipolar disorder which has potential to be easily
rolled out to patients.
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Bipolar disorder is a severe recurrent disorder of mood
and behaviour characterised by episodes of depression
and mania or hypomania[1]. A clinical spectrum of bipo-
lar disorder affects between 3–5% of the population and
results in considerable lifelong social and occupational
impairment [2-4]. Most of the morbidity associated with
this disorder is caused by recurrent depressive episodes
and chronic, low-grade depressive symptoms, which are
present in most patients for at least half of their life-
time[5,6].
There is currently considerable uncertainty about how
best to treat these chronic depressive symptoms which
have an enormous impact on the quality of life and func-
tioning of large numbers of bipolar patients [7]. Much of
this uncertainty concerns the use of antidepressants. Sev-
eral studies suggest that a significant proportion of
patients (between 30–50%) will respond poorly to anti-
depressants and may develop a chronic, cycling course of
illness with more frequent depressive episodes, more sui-
cidal behaviour and, in the longer-term, more treatment-
resistance [8,9]. As a result, there is an urgent need to
develop alternative, non-pharmacological interventions
which might help to address chronic depressive features
of the illness, as well as preventing manic relapses in the
longer-term. Some studies of cognitive behavioural ther-
apy for bipolar disorder have been positive [10-12]. How-
ever, a recent large randomised controlled trial found that
benefit was limited to a small sub-group of patients [13].
Psychoeducational interventions, which tend to employ
some cognitive-behavioural techniques in the context of
adjunctive pharmacological management, have emerged
as more promising long-term therapeutic options for
bipolar disorder [14-18].
Most of the bipolar psychoeducation research to date has
focused on group interventions [16-19]. Colom and Vieta
have pioneered group psychoeducational interventions
for bipolar disorder and have demonstrated that these
programmes are effective in preventing relapse, are eco-
nomically viable and are highly acceptable to patients
[16,17,19]. A potential disadvantage of group psychoedu-
cation is the considerable cost in terms of therapist time.
As a result, group psychoeducation for bipolar disorder is
not routinely available within the National Health Service
(NHS). In order to make bipolar psychoeducational mate-
rial more easily available to patients we have developed a
novel, interactive, web-based, psychoeducational package
for bipolar disorder which draws heavily on the positive
aspects of the Barcelona model [16] and which has been
produced in close consultation with patients, their fami-
lies, carers and health professionals http://www.beating
bipolar.org/modules/flash/index.html.
To our knowledge, there are no published data on the
effectiveness of interactive or web-based psychoeduca-
tional programmes for bipolar disorder. The aim of the
study is to assess a novel interactive psychoeducational
intervention for bipolar disorder within an exploratory
randomised controlled trial. The primary objective will be
to assess whether those participating in the "Beating Bipo-
lar" programme have improved quality of life compared
to those in the control group. Secondary objectives
include assessing whether those participating in the Beat-
ing Bipolar programme have improved scores on func-
tioning, insight and depressive and manic symptoms and
episodes. An assessment of costs and a detailed process
evaluation exploring barriers, feasibility and acceptability
of the intervention will also be completed. This paper
describes the design of the trial.
Methods/design
This is an exploratory (phase II) individually randomised
controlled trial.
The intervention: "Beating Bipolar"
The intervention was developed using an iterative process
involving focus groups with patients, their carers and fam-
ilies and health professionals. The purpose of these
groups was to advise on the design and content of the pro-
gramme, as well as to revise and refine the intervention.
Final decisions on the content were made by the research
team. This process took 7 months. The primary focus of
the intervention is the recognition and self-management
of chronic depressive symptoms, depressive relapse and
associated functional impairments. The intervention
involves a blending of different delivery mechanisms,
with initial face-to-face delivery, followed by written and
web-based interactive delivery of factual content and
ongoing support via a web forum. The web-based content
requires the reader to be engaged in a number of interac-
tive exercises in order to maximise long-term retention of
the material.
The key areas covered in the package are: i) the accurate
diagnosis of bipolar disorder; ii) the causes of bipolar dis-
order; iii) the role of medication; iv) the role of lifestyle
changes; v) relapse prevention and early intervention; vi)
psychological approaches; vii) gender-specific considera-
tions and viii) advice for family and carers. The 8 modules
are delivered online on a fortnightly basis over a four-
month period. In order to maintain engagement, the
modules are relatively brief at 20–30 minutes per module.
There is an initial face-to-face introductory meeting with
participants designed to engage them with the pro-
gramme as well as to illustrate its use. Thereafter, partici-
pants will log onto the website and complete a module.
Each module is then discussed within an online forum for
participants, which will be moderated by a consultantPage 2 of 8
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and will allow us to provide clarification of module con-
tent, answer questions from participants and provide on-
going support and engagement. The online forum will
also be important in terms of assessing the acceptability of
the intervention.
Outcome measures
The primary outcome measure is the World Health
Organisation Quality of Life assessment tool, Brief version
(WHOQOL-Bref) [20] (see Table 1). This provides an
assessment of overall quality of life. It is comprised of
scores within four separate domains (physical health, psy-
chological health, social relationships and environment).
It is a reliable, valid and widely-used measure of quality of
life in psychiatric out-patient settings [21]. A review con-
cluded that there is currently no quality of life measure for
specific use in bipolar patients, however the WHO-QOL is
recommended for this population [22].
Secondary outcomes will examine functioning using the
Global Assessment of Functioning (GAF) and Functioning
Assessment Short Test (FAST) scales and insight, using the
Schedule of Assessment of Insight (SAI). Current depres-
sive symptoms according to the Montgomery Asberg
Depression Rating Scale (MADRS) and current manic
symptoms according to the Young Mania Rating Scale
scale (YMRS), will also be compared between the two
groups. Using the Mini International Neuropsychiatric
Interview (MINI), the number and severity of depressive
and manic symptoms and number and timing of episodes
of depression and mania or hypomania experienced dur-
ing the follow-up period will be compared between
groups (this will permit assessments of time to relapse)
Sample size
Based on our own work and the work of others using the
WHOQOL-Bref in mood disordered patients, we expect
that the mean score for patients at entry will be 65 (stand-
ard deviation 14.4) and that a meaningful clinical
response will be a difference between experimental and
control groups of 10 or more points [23]. For an 80%
chance of detecting this difference on the WHOQOL-Bref,
at a significance level of 0.05, 32 patients are needed in
each arm of the trial at follow-up. We will recruit 50
patients into each arm of the study which, allowing for a
30% attrition rate, will mean that 35 patients in each arm
will complete the trial. Our recruitment strategy and our
extensive contacts with local clinical services and patient
Table 1: Outcome Measures and Assessments
Baseline assessment Interim assessment
(at end of treatment)
Final assessment
(6 mth after treatment)
By interview at t = 0 months By post at t = 4 months By interview at t = 10 months
Primary Outcome:
WHOQOL-Bref + + +
Secondary Outcomes:
MINI assessment + --- +
MADRS + --- +
YMRS + --- +
GAF + --- +
FAST + --- +
SAI + --- +





WHOQOL-Bref: World Health Organisation Quality of Life Assessment, Brief Version; MINI: Mini International Neuropsychiatric Interview; 
MADRS: Montgomery Asberg Depression Rating Scale; YMRS: Young Mania Rating Scale; GAF: Global Assessment of Functioning Scale; FAST: 
Functioning Assessment Short Test; SAI: Schedule of Assessment of InsightPage 3 of 8
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the trial is realistic and achievable.
Recruitment
Participants will be identified and recruited from multiple
sources across South Wales, including Cardiff Primary
Care Practices, Cardiff Community Mental Health Teams
(CMHTs) and local branches of the Manic Depression Fel-
lowship. Our recruitment strategy will be aided by using
the resources of the Mental Health Research Network for
Wales (MHRN-Cymru) and the Primary Care Mental
Health Research Network in Wales (PCMHRN-Cymru).
Inclusion criteria
The main inclusion criterion for this study will be a diag-
nosis of DSM-IV bipolar disorder (including type I and
type II) currently in clinical remission. Clinical remission
has been chosen as an inclusion criterion because this is
an exploratory trial of an intervention which requires par-
ticipants to be able to fully engage with psychoeduca-
tional material. It is also the case that the primary
outcome is a measure of quality of life rather than clinical
symptoms. Diagnosis will be assessed using the Mini
International Neuropsychiatric Interview (MINI) [24] and
clinical remission will be defined as not fulfilling diagnos-
tic criteria for a depressive, manic or mixed affective epi-
sode during the preceding 3 month period, plus a current
Montgomery Asberg Depression Rating Scale (MADRS)
score of less than or equal to 10 [25,26] and a Young
Mania Rating Scale score of less than or equal to 8 [27].
These MADRS and YMRS threshold scores are widely
accepted correlates of symptomatic remission in bipolar
disorder. Participants must also be aged between 18 and
65 for inclusion in this study.
Exclusion criteria
These will include an inability to engage fully in the psy-
choeducational programme (for example, because of cog-
nitive impairment or not having English language of a
sufficient level), not meeting diagnostic criteria for bipo-
lar disorder, and not being in clinical remission according
to the definitions above. Given that this is an exploratory
trial, no other exclusion criteria will be specified.
Trial procedures: consent, baseline assessments and 
randomisation
All potential participants will receive an invitation letter
and a detailed information sheet about the study inviting
them to approach the research team if they are interested
in taking part. They will be asked to provide written con-
sent before being screened for the inclusion and exclusion
criteria using the MINI interview and MADRS/YMRS
assessments (see Figure 1). Participants identified as eligi-
ble will also complete the WHOQOL-Bref [20], the GAF
Scale [28], the FAST [29] and the SAI [30]. Participants
will be individually randomised remotely using compu-
ter-generated number lists to either, the Beating Bipolar
intervention plus treatment-as-usual (TAU) or TAU alone.
Delivery of the intervention will begin within 2 weeks of
randomisation. Both arms of the study will receive TAU,
which will be ongoing care by CMHTs and/or General
Practitioners (GPs). We will attempt to minimise poten-
tial contamination between groups by giving those in the
experimental group individual logins to the website and
emphasising the importance of keeping these details pri-
vate. We will also monitor use of the software and explore
possible contamination during the process evaluation
interviews. In order to minimise demoralisation and
drop-out in the control arm, all participants will be
offered the intervention at the end of the follow-up period
if the intervention appears to be effective. The interven-
tion will last for 4 months. There will be an interim assess-
ment at the end of the intervention, which will be a postal
questionnaire of the WHOQOL-Bref. The primary out-
come point will be 10 months from randomisation and
all measures will be reassessed at this point (Figure 1 and
Table 1).
Process evaluation
A process evaluation will be conducted to evaluate
whether the intervention was carried out in accordance
with the trial protocol, to examine the feasibility and effi-
cacy of the programme and to identify barriers to effective-
ness as well as areas for improvement. We will map the
patients' participation in the forum and use of the psych-
oeducational programme. We will be able to examine for
example, how often participants log in and which pages
they use. After the follow-up is complete, qualitative inter-
views with around 20 of the participants in the interven-
tion group will be conducted to evaluate issues such as
acceptability of the intervention, engagement, aspects par-
ticipants found particularly useful, problems leading to
non-adherence and possible contamination between
groups. These participants will be purposively sampled to
include both males and females from different age groups
and will also include a range of levels of engagement with
the package.
Assessment of Costs
We will also conduct an assessment of the direct costs of
the intervention and identify its key cost consequences
e.g. reductions in demands on general practitioners. Cost
of the intervention will be assessed by monitoring
resources used and valuing them using standard methods
[31]. Participants will be asked to report their use of other
NHS resources, social services and time off work. The time
they spend on-line will be monitored.Page 4 of 8
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Statistical analyses
The primary analysis will be an intention-to-treat analysis
and will compare the WHOQOL-Bref scores between the
two groups whilst controlling for baseline WHOQOL-Bref
scores using ANCOVA. Secondary outcome analyses will
be performed similarly controlling for baseline and we
will explore the impact of non-engagement with the inter-
vention by undertaking exploratory complier adjusted
(CACE) analyses[32]. Analysis of adherence to the pro-
gram will also be undertaken using logistic regression. No
interim analyses or formal subgroups analyses are
planned.
Qualitative analyses
The interviews will be audio recorded and transcribed. We
will employ standard thematic content analysis tech-
niques[33] This method of analysis is essentially a process
of summarization, categorisation and counting frequency
of responses. The transcripts will be closely examined to
identify themes and categories. Codes will be applied to
these broad themes which will then be broken down fur-
ther into sub-codes. Agreement on concepts and coding
will be sought between members of the research team in
order to ensure reliability. We will seek to identify com-
monly expressed themes as well as unusual cases. A pro-
portion of the data (20%) will be coded by two different
team members to check on reliability of the coding
scheme. The interviewing will be iterative; where new
themes emerge we will incorporate them into the inter-
views.
Analyses of costs
As this is an exploratory study a full economic evaluation
would be premature. Nevertheless, the assessment of the
costs and cost consequences discussed above will inform
the design of the definitive study (if justified by the results
of this exploratory study) by identifying the key cost driv-
BIPED Trial DesignFigure 1
BIPED Trial Design.
  
TAU: Treatment as usual 
Recruitment from Cardiff Primary Care Practices, Cardiff Community Mental Health Teams and the 
Manic Depression Fellowship in Wales (MDF-Cymru) 




Beating Bipolar plus TAU 
(n=50) 
TAU (n=50)t = 0 months 
t = 4 months Interim assessments by post Interim assessments by post 
Outcome assessments by interview Outcome assessments by interview t = 10 months Page 5 of 8
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major impact on productivity (assessed by monitoring
time off work) then an NHS perspective would not be
appropriate for the economic evaluation to be undertaken
alongside the definitive trial. The exploratory trial will
only assess costs, since for cost effectiveness purposes a
utility based generic measure of health status such as the
EuroQol (EQ-5D) [34] would be needed to produce an
incremental cost effectiveness ratio which could allow
comparison with other interventions. This is not neces-
sary at this stage.
Discussion
This trial will be the first to evaluate the effectiveness and
acceptability of a novel web-based psychoeducational
intervention for bipolar disorder. This exploratory trial
will assess the impact of the programme on the quality of
life, functioning and symptom profile of patients with
bipolar disorder. In combination with the economic eval-
uation and the process measures assessing acceptability
and engagement with the intervention, data from this trial
will substantially inform the design of a larger (phase III)
randomised controlled trial of this intervention.
Strengths of the study
We have utilised our experience in the development and
evaluation of web-based learning programmes in differ-
ent topic areas to maximise the design aspects and usabil-
ity of the programme[35]. In addition, we have involved
patients, their families, carers and health professionals in
the development of the content and design. We have also
incorporated findings from recent studies into the design
and content of the intervention. For example, the content
draws heavily on the positive aspects of a group based psy-
choeducation programme which has been successfully
evaluated in a trial[16]. A recent qualitative study examin-
ing patients views of a group based psychoeducation
intervention identified three main themes of importance;
the treatment of bipolar disorder, perception of others
and the support of the group [36]. These aspects are all
included in this programme.
We have included a module specifically for family or car-
ers of bipolar patients because we felt that their support
and guidance was instrumental in the way that bipolar
patients cope with their illness. One recent study examin-
ing a psychoeducation intervention for caregivers of bipo-
lar patients in remission found a reduction in mood
recurrence and longer intervals without relapse for manic
or hypomanic episodes[37].
Challenges
In order to ensure that the programme would be available
to as many participants from different backgrounds as
possible and to allow those who do not have internet
access at home to be involved in this study, we will liaise
with local libraries in South Wales to provide free internet
access and support for those participants who require it.
Encouraging patients with a bipolar diagnosis to engage
with the programme may be challenging given the cogni-
tive deficits and emotional difficulties associated with the
condition. However, we will be recruiting patients who
are in remission and we have tried to design the pro-
gramme to take account of these issues. We have paid
close attention to engagement, from the initial meeting
through the general appeal and interactivity of the pro-
gramme to the peer support via the forum. One of the fac-
tors affecting the success of group psychoeducation
programmes is likely to be peer group support. We have
tried to incorporate this via the initial meeting and the
forum. However it remains to be seen whether the forum
peer support and feedback can sufficiently fulfil this role.
It has been suggested that psychoeducation should be
delivered as part of a routine package of care for bipolar
disorder. A systematic review concluded that there was
evidence that psychoeducation enhances patients' knowl-
edge of the disorder and of treatments available. It also
leads to decreases in relapse and improves compliance
with treatment[38]. The authors recommend psychoedu-
cation in the management of bipolar disorder. This web
based method of delivering psychoeducation could pro-
vide a cost-effective method for achieving this.
Conclusion
In summary, bipolar disorder is common, under-recog-
nised and poorly managed. It is associated with consider-
able personal and social impairment and as a chronic, life-
long and relapsing condition it has an enormous impact
on the economy. As noted above, there is an urgent need
to develop treatments which are simple, efficacious, cost-
effective, acceptable to patients and that have the poten-
tial to be widely applied. This trial will assess whether
Beating Bipolar fulfils these criteria.
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